Skip to main content
OpenTrials
Completed

NCT Number: NCT05326607

Pilot Clinical Investigation of Adaptative Eyeglasses for the Correction of Presbyopia

This study is a pilot clinical investigation of adaptive eyeglasses for the correction of presbyopia. The goal of this clinical investigation is to assess IMD safety and to obtain patient feedback on the usefulness of the Laclarée eyeglasses, through subjective clinical measures and qualitative evaluations. This is an exploratory investigation.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU Saint-Etienne Hôpital Nord, Service d'Ophtalmologie 25, boulevard Pasteur

Saint-Etienne, 42055, France

About this study

Presbyopia is a visual impairment caused by the normal aging of the eye lens and resulting in progressive loss of accommodation. As a consequence, from the onset of presbyopia occurring around 40-45 years old, the eye has growing trouble focusing at near and intermediate distances. Millions of presbyopes encounter difficulties with current corrective solutions, leading to vision and postural discomfort. Laclarée's adaptive eyeglasses are providing an alternative solution, closer to the native crystalline accommodation. Besides an enhanced field-of-view, these eyeglasses offer a disruptive ergonomics where the glasses automatically adjust to the wearer's need to provide clear vision at all distances and can be electronically recalibrated to adjust the delivered addition throughout presbyopia.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient >18 years of age, male or female who has given explicit informed consent (dated and signed)
  • Diagnosed with presbyopia
  • A wearer whose current corrective solution is a pair of progressive lenses that provide clear vision at both distance and near vision (worn at least 5 times per week for 4 hours per day), or, a wearer who has rejected progressive glasses that provide clear vision at both distance and near vision and who uses another corrective solution that provides clear vision at both distance and near vision (bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia)
  • Patient with a distance visual acuity of 10/10 at least with current corrective solution
  • Patient with a visual acuity of P2 at least in near vision with current corrective solution
  • Patient with at least 10/10 distance vision once corrected with contact lenses for the test
  • Inter-pupillary distance in distance vision between 55 and 71mm
  • Distance from temple-to-temple not exceeding 161mm
  • Addition greater than or equal to 1.75D: Add≥1.75D
  • Sphere strictly between -6D and +4D: -6D<S<+4D
  • Cylinder below 1.75D:C<1.75D
  • Patient uses a computer (at least 3 times a week in private and/or work settings).
  • Affiliation to a social security scheme
  • French-speaking (fluent).
  • Patient willing to participate in the study.

Exclusion criteria

  • Patient under tutorship or guardianship.
  • Patient unable to understand the study procedures and therefore to provide free and informed consent
  • Patient with reading difficulties
  • Patient with multifocal implants
  • Patient who has undergone multifocal surgery
  • Patient with prism correction
  • Patient with a current or past eye condition that may adversely affect vision
  • Patient being treated or having undergone surgery likely to adversely affect vision
  • Patient with mobility problems that would prevent tests and workshops from being carried out
  • Patient intolerant to wearing contact lenses for a few hours (only for presbyopes with ametropia)
  • Patient who is pregnant or breastfeeding
  • Patient already included once in the study
  • Patient placed in an institution based on a judicial or regulatory ruling, held in psychiatric department, in state-run prison, or employed by the study research sites or by the sponsor.

Treatment and study plan

Prototype of adaptive eyeglasses

Device

The tested investigational medical device is a prototype of semi-integrated eyeglasses.

COMPARATOR

Device

The comparator is either a pair of progressive lenses that provide clear vision at both distance and near vision, either, for wearers who have rejected progressive glasses, an alternative solution providing clear vision at both distance and near vision which can consist of bifocal glasses, multifocal or monovision lenses, multiple pairs of glasses or one pair for cases of emmetropia.

Primary outcomes

  1. IMD safety evaluation

    Time frame: 2 hours

    To evaluate the IMD safety : Collection of adverse events.

Secondary outcomes

  1. Exploratory evaluation of the IMD - controlled tests assessing visual acuity and performance on visual tasks

    Time frame: 2 hours

    To make an exploratory evaluation of the IMD performance on patient vision quality, when compared to that obtained with the patient usual personal eyewear (comparator) : Subjective measures on controlled tests assessing visual acuity and performance on visual tasks.

  2. Exploratory evaluation of the IMD - a questionnaire assessing vision quality

    Time frame: 2 hours

    To make an exploratory evaluation of the IMD performance on patient vision quality, when compared to that obtained with the patient usual personal eyewear (comparator) : Subjective measures on questionnaires.

  3. Exploratory evaluation of the IMD - patient qualitative feedback

    Time frame: 2 hours

    To make an exploratory evaluation of the IMD performance on patient vision quality, when compared to that obtained with the patient usual personal eyewear (comparator) : Collection of patient feedback.

Sponsors and collaborators

Lead sponsor

Laclaree

Industry

Collaborators

  • Iris Pharma

Registry information

Official study title

Pilot Clinical Investigation of Adaptive Eyeglasses for the Correction of Presbyopia

Acronym: eve-1

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Apr 13, 2022
Registry last updated
Apr 13, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.